Overview

This trial is active, not recruiting.

Condition colorectal cancer
Treatments capecitabine, irinotecan hydrochloride
Phase phase 2
Sponsor Federation Francophone de Cancerologie Digestive
Start date June 2006
Trial size 78 participants
Trial identifier NCT00303745, CDR0000453857, EU-20545, EUDRACT-2004-004742-40, FFCD-0305

Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether irinotecan and capecitabine are more effective than irinotecan alone in treating colorectal cancer.

PURPOSE: This randomized phase II trial is studying irinotecan and capecitabine to see how well they work as second-line therapy compared to irinotecan alone in treating older patients with progressive, metastatic colorectal cancer that cannot be removed by surgery.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
Objective response
time frame:
Stable disease rate
time frame:

Secondary Outcomes

Measure
Tolerability
time frame:
Quality of life
time frame:
Progression-free and overall survival
time frame:

Eligibility Criteria

Male or female participants at least 75 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed metastatic adenocarcinoma of the colon or rectum - Unresectable disease - Documented progressive disease during first-line/palliative chemotherapy - Measurable disease ≥ 1 cm that is outside prior radiation field - No brain metastases PATIENT CHARACTERISTICS: - WHO performance status 0-2 - Life expectancy ≥ 3 months - No contraindication to chemotherapy - Creatinine clearance ≥ 40 mL/min - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - Alkaline phosphatase ≤ 3 times normal (5 times normal if hepatic involvement) - Bilirubin ≤ 1.5 times normal - Transaminases ≤ 5 times normal - No symptomatic coronary disease or cardiac insufficiency - No enteropathy or chronic diarrhea - No unresolved intestinal occlusion or subocclusion - No history of severe unexpected reaction to a fluoropyrimidine - No other active malignancy in the past 2 years - No hypersensitivity to irinotecan hydrochloride or its excipients - No hypersensitivity to capecitabine or fluorouracil PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior extensive resection - No concurrent sorivudine or similar analogs (e.g., brivudine) - No other concurrent anticancer therapy - Concurrent radiotherapy allowed for nontarget lesions

Additional Information

Official title Randomized Study of Second-Line Therapy Comprising Irinotecan With or Without Capecitabine in Patients Aged At Least 75 Years With Colorectal Cancer
Description OBJECTIVES: Primary - Compare the objective response or stable disease rate in elderly patients with unresectable, progressive, metastatic colorectal cancer treated with irinotecan hydrochloride with vs without capecitabine. Secondary - Compare the tolerability of these regimens in these patients. - Compare the quality of life and ability to maintain self-sufficiency of patients treated with these regimens. - Compare the progression-free and overall survival of patients treated with these regimens. OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified according to participating center, WHO performance status (0 or 1 vs 2), number of associated comorbidities (Charlson index 0-2 vs > 2), and age (75-79 vs ≥ 80). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive oral capecitabine on days 1-14 and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 12 weeks thereafter. After completion of study therapy, patients are followed every 12 weeks. PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in July 2008.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).